In this week’s clinical update, we take a look at a CRISPR-engineered T cell receptor-T cell therapy that is designed to treat all genetic subtypes of...
In a recent landmark paper, Dr Bo Wang and his colleagues at Kyoto University used CRISPR to generate triple-knockout, hypoimmunogenic T cells from...
This week’s clinical update looks at a Phase 1/2 trial for VOR33, a CRISPR-Cas9-edited haematopoietic stem and progenitor cell (HSPC) therapy under...
Two weeks ago, we hosted a CMN webinar on CRISPR Delivery Systems. Several hundred attendees from all continents tuned in for the live event. Here's a...
This week we bring you a clinical trial update on GC027, a CRISPR-edited CAR T-cell therapy for relapsed or refractory CD7+ T cell acute lymphoblastic...
This week’s update looks at a Phase 1/2 study for ALLO-501A, a TALEN-edited CAR T-cell therapy for large B-cell lymphoma.
This week’s gene-editing clinical trial update looks at a universal dual specificity CD19 and CD20/CD22 CAR-T cell immunotherapy that is being...
This year CRISPR broke new ground in medicine. We saw the first CRISPR gene editing directly in the body, CRISPR took huge wins in clinical trials and...
